Recombinant Human KIR2DL3/CD158b2 Fc Chimera Protein, CF
Recombinant Human KIR2DL3/CD158b2 Fc Chimera Protein, CF Summary
Accession # P43628
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 500 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
KIR2DL3 (2DL3, formerly NKAT2, designated CD158b2) is a 341 amino acid (aa) type I transmembrane glycoprotein that belongs to the human killer cell Ig‑like receptor (KIR) family of molecules (1, 2). KIRs are expressed on human CD56dim NK cells and T cell subsets, and regulate effector functions in the innate immune system (1-3). KIRs are named for the number of Ig‑like domains (2D or 3D) in the extracellular domain (ECD), and whether they have long or short (L, S) cytoplasmic tails (1‑3). Individuals will express varying subsets of inhibiting and activating KIRs with varying polymorphisms (1, 4). Like other inhibiting KIRs, KIR2DL3 has two ITIM domains within its long tail that block activating receptor clustering (2). Within the ECD, KIR2DL3 shares very high aa sequence identity (98%) with KIR2DL2. The two segregate as alleles of the same gene; both recognize Asn80‑containing HLA‑C1 and, more weakly, Lys80‑containing C2 allotypes (1, 5). Extracellular aa identity is also high for KIR2DL1 (93%). The three molecules together recognize and inhibit NK cytotoxicity against cells expressing any HLA‑C allotype, allowing for self‑recognition (1‑3). Compared with KIR2DL2, KIR2DL3 shows lower avidity for HLA‑C1 ligands; when compared to KIR2DL1, KIR2DL3 has lower avidity but broader specificity for HLA-C1 ligands (1, 5, 6). Configurations of inhibiting and activating KIR can alter an individual’s susceptibility to viral and autoimmune diseases and leukemia (1‑3). For example, rheumatoid arthritis patients that are positive for KIR2DL3 and negative for KIR2DS3 have an earlier disease diagnosis (7).
- Purdy, A.K. and Campbell, K.S. (2009) Cancer Biol. Ther. 8:13.
- Lanier, L. L. (2005) Annu. Rev. Immunol. 23:225.
- Kulkarni, S. et al. (2008) Semin. Immunol. 20:343.
- Middleton, D. and F. Gonzelez (2009) Immunology 129:8.
- Moesta, A.K. et al. (2008) J. Immunol. 180:3969.
- Hilton, H.G. et al. (2012) J. Immunol. 189:1418.
- Majorczyk, E. et al. (2007) Genes Immun. 8:678.
Citations for Recombinant Human KIR2DL3/CD158b2 Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 3
Filter your results:
The Activating Human NK Cell Receptor KIR2DS2 Recognizes a ?2-Microglobulin-Independent Ligand on Cancer Cells
Authors: L Thiruchelv, SE Hoelsbrekk, PC Saether, E Gyllensten, D Pende, S Fossum, MR Daws, E Dissen
J. Immunol, 2017;0(0):.
Sample Types: Whole Cells
Applications: Binding Assay
Peptide selectivity discriminates NK cells from KIR2DL2- and KIR2DL3-positive individuals.
Authors: Cassidy S, Mukherjee S, Myint T, Mbiribindi B, North H, Traherne J, Mulder A, Claas F, Purbhoo M, Das J, Khakoo S
Eur J Immunol, 2015;45(2):492-500.
Sample Types: Protein
ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors.
Authors: Cifaldi L, Romania P, Falco M, Lorenzi S, Meazza R, Petrini S, Andreani M, Pende D, Locatelli F, Fruci D
Cancer Res, 2015;75(5):824-34.
Sample Types: Whole Cells
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human KIR2DL3/CD158b2 Fc Chimera Protein, CF
Average Rating: 4 (Based on 2 Reviews)
Have you used Recombinant Human KIR2DL3/CD158b2 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Reason for Rating: good quality